Teng Bunyen, Ledent Catherine, Mustafa S Jamal
Department of Physiology and Pharmacology, West Virginia University Health Sciences Center, Morgantown, WV 26506-9104, USA.
J Mol Cell Cardiol. 2008 May;44(5):905-14. doi: 10.1016/j.yjmcc.2008.03.003. Epub 2008 Mar 12.
In this study, we looked into possible compensatory changes of other adenosine receptors (ARs) in A(2A) genetic knockout mice (A2AKO) as well as the functional role of nitric oxide (NO) in A(2A) AR-mediated vasodilation. Gene expression of ARs from coronary arteries of A(2A) AR wild type mice (A2AWT) and A2AKO was studied using real-time PCR. Functional studies were carried out in isolated heart and isolated coronary artery preparations. A(2B) AR was found to be 4.5 fold higher in A2AKO than in A2AWT, while A(2A) AR expression was absent in A2AKO. There was no difference in A(1) and A(3) ARs between WT and KO animals. The concentration-relaxation curve for adenosine-5'-N-ethylcarboxamide (NECA, non-selective AR agonist) in isolated coronary arterial rings in A2AKO was shifted to the left when compared to A2AWT. The concentration-response curve for A(2B) selective agonist (BAY 60-6583) was also shifted to the left in A2AKO hearts. L-NAME, a non-specific NO synthase inhibitor, did not affect baseline coronary flow (CF) until the concentration reached 10 microM in A2AWT (76.32+/-11.35% from baseline, n=5). In A2AKO, the CF decreased significantly by L-NAME only at a higher concentration (100 microM, 93.32+/-5.8% from baseline, n=5). L-NMA (1 microM, n=4), another non-specific NO synthase inhibitor, also demonstrated similar results in decreasing CF (59.66+/-3.23% from baseline in A2AWT, while 81.76+/-8.91% in A2AKO). It was further demonstrated that the increase in CF by 100 microM NECA was significantly blunted with 10 microM L-NAME (377.08+/-25.23% to 305.41+/-30.73%, n=9) in A2AWT but not in A2AKO (153.66+/-22.7% to 143.88+/-36.65%, n=5). Similar results were also found using 50 nM of CGS-21680 instead of NECA in A2AWT (346+/-22.85 to 277+/-31.39, n=6). No change in CF to CGS-21680 was noted in A(2A)AKO. Our data demonstrate, for the first time, that coronary A(2B) AR was up-regulated in mice deficient in A(2A) AR. We also provide direct evidence supporting a role for NO in A(2A) AR-mediated coronary vasodilation. The data further support the role for A(2A) AR in the regulation of basal coronary tone through the release of NO.
在本研究中,我们探究了A2A基因敲除小鼠(A2AKO)中其他腺苷受体(ARs)可能的代偿性变化,以及一氧化氮(NO)在A2A AR介导的血管舒张中的功能作用。使用实时PCR研究了A2A AR野生型小鼠(A2AWT)和A2AKO冠状动脉中ARs的基因表达。在离体心脏和离体冠状动脉标本中进行了功能研究。发现A2AKO中A2B AR比A2AWT高4.5倍,而A2AKO中不存在A2A AR表达。WT和KO动物之间A1和A3 ARs没有差异。与A2AWT相比,A2AKO离体冠状动脉环中腺苷-5'-N-乙基羧酰胺(NECA,非选择性AR激动剂)的浓度-舒张曲线向左移动。A2B选择性激动剂(BAY 60-6583)在A2AKO心脏中的浓度-反应曲线也向左移动。L-NAME,一种非特异性一氧化氮合酶抑制剂,在A2AWT中直到浓度达到10μM时才影响基础冠状动脉血流(CF)(相对于基线为76.32±11.35%,n = 5)。在A2AKO中,仅在较高浓度(100μM,相对于基线为93.32±5.8%,n = 5)时L-NAME才使CF显著降低。另一种非特异性一氧化氮合酶抑制剂L-NMA(1μM,n = 4)在降低CF方面也显示出类似结果(A2AWT中相对于基线为59.66±3.23%,而A2AKO中为81.76±8.91%)。进一步证明,在A2AWT中,100μM NECA引起的CF增加在加入10μM L-NAME后显著减弱(从377.08±25.23%降至305.41±30.73%,n = 9),而在A2AKO中未减弱(从153.66±22.7%降至143.88±36.65%,n = 5)。在A2AWT中使用50 nM的CGS-21680代替NECA也得到了类似结果(从346±22.85降至277±31.39,n = 6)。A2AKO中对CGS-21680的CF没有变化。我们的数据首次证明,在缺乏A2A AR的小鼠中冠状动脉A2B AR上调。我们还提供了直接证据支持NO在A2A AR介导的冠状动脉舒张中的作用。数据进一步支持A2A AR通过释放NO在调节基础冠状动脉张力中的作用。